Pathway inhibitors for bridging to allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL)

被引：0
|
作者：
Hahn, M. [1 ]
Dietrich, S. [1 ]
Hain, S-A [2 ]
Hegenbart, U. [1 ]
Rieger, M.
Scheuer, B.
Ho, A. D. [1 ]
Dreger, P. [1 ]
机构：
[1] Heidelberg Univ, Med Klin 5, Heidelberg, Germany
[2] St Marien Krankenhaus, Med Klin 3, Siegen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V61
引用
收藏
页码：13 / 14
页数：2
相关论文
共 50 条
  • [31] Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia
    Zahid, Mohammad Faizan
    Ali, Natasha
    MEDICAL ONCOLOGY, 2015, 32 (07)
  • [32] The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia
    Banerji, Versha
    Johnston, James B.
    Seftel, Matthew D.
    TRANSFUSION AND APHERESIS SCIENCE, 2007, 37 (01) : 57 - 62
  • [33] Progressive Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Cell Transplantation
    Jitawatanarat, Potjana
    Desai, Arpita
    Sharda, Pradeep
    Liu, Hong
    Ross, Maureen
    Hernandez-Llizaliturri, Francisco J.
    McCarthy, Philip L.
    Chen, George L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (10): : 1203 - 1206
  • [34] The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review
    Puckrin, Robert
    Shafey, Mona
    Storek, Jan
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [35] EFFICACY OF RESCUE IMMUNOTHERAPY AND SURVIVAL IN PATIENTS WITH HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAD CLINICAL RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
    Hahn, M.
    Dietrich, S.
    Herth, I.
    Hegenbart, U.
    Walter, E.
    Rieger, M.
    Stadtherr, P.
    Bondong, A.
    Ho, A. Dick
    Dreger, P.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S142 - S143
  • [36] Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia
    Radich, JP
    Olavarria, E
    Apperley, JF
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (03) : 685 - +
  • [37] Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial
    Kramer, Isabelle
    Stilgenbauer, Stephan
    Dietrich, Sascha
    Bottcher, Sebastian
    Ritgen, Matthias
    Bunjes, Donald
    Zeis, Matthias
    Stadler, Michael
    Bittenbring, Joerg Thomas
    Hegenbart, Ute
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Dohner, Hartmut
    Dreger, Peter
    BLOOD, 2016, 128 (22)
  • [38] Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial
    Kraemer, I.
    Stilgenbauer, S.
    Dietrich, S.
    Boettcher, S.
    Bunjes, D. W.
    Zeis, M.
    Stadler, M.
    Bittenbring, J. T.
    Uharek, L.
    Scheid, C.
    Hegenbart, U.
    Ho, A.
    Anthony, D.
    Hallek, M.
    Kneba, M.
    Schmitz, N.
    Doehner, H.
    Dreger, P.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S424 - S424
  • [39] Minimal Tbi-based conditioning followed by HLA-identical hematopoietic stem cell transplantation (HSCT) in patients with chronic lymphocytic leukemia (CLL)
    Soligo, D
    Ibatici, A
    Annaloro, C
    Frison, S
    Morandi, P
    Cortelezzi, A
    Lambertenghi Deliliers, G
    BONE MARROW TRANSPLANTATION, 2002, 29 : S159 - S160
  • [40] Allogeneic hematopoietic stem cell transplantation for treatment of acute lymphocytic leukemia.
    Ren, HY
    Chen, H
    Huang, XJ
    Xu, LP
    Zhang, YC
    Liu, DH
    Guo, NL
    Lu, DP
    BLOOD, 2003, 102 (11) : 463B - 463B
12345